Search hospitals > New York > Rochester
Rochester General Hospital
Claim this profileRochester, New York 14621
Global Leader in Stroke
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Heart Failure
Conducts research for Lung Cancer
111 reported clinical trials
16 medical researchers
Summary
Rochester General Hospital is a medical facility located in Rochester, New York. This center is recognized for care of Stroke, Breast Cancer, Cancer, Heart Failure, Lung Cancer and other specialties. Rochester General Hospital is involved with conducting 111 clinical trials across 187 conditions. There are 16 research doctors associated with this hospital, such as Jeremiah Depta, MD, Peter W. Bushunow, Sheema Chawla, and Bipul Baibhav, MD.Area of expertise
1Stroke
Global Leader2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Jeremiah Depta, MDRochester General Hospital5 years of reported clinical research
Studies Heart Failure
Studies Stroke
7 reported clinical trials
10 drugs studied
Peter W. BushunowRochester General Hospital9 years of reported clinical research
Studies Colorectal Cancer
Studies Ovarian Cancer
2 reported clinical trials
21 drugs studied
Sheema ChawlaRochester General Hospital5 years of reported clinical research
Studies Breast Cancer
2 reported clinical trials
5 drugs studied
Bipul Baibhav, MDRochester General Hospital5 years of reported clinical research
Studies Tricuspid Regurgitation
Studies Tricuspid Valve Disease
2 reported clinical trials
3 drugs studied
Clinical Trials running at Rochester General Hospital
Non-Small Cell Lung Cancer
Lung Cancer
Pancreatic Carcinoma
Cancer
Multiple Myeloma
Aortic Valve Stenosis
Tricuspid Regurgitation
Mitral Valve Regurgitation
Pancreatic Cancer
Squamous Cell Carcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Rochester General Hospital?
Rochester General Hospital is a medical facility located in Rochester, New York. This center is recognized for care of Stroke, Breast Cancer, Cancer, Heart Failure, Lung Cancer and other specialties. Rochester General Hospital is involved with conducting 111 clinical trials across 187 conditions. There are 16 research doctors associated with this hospital, such as Jeremiah Depta, MD, Peter W. Bushunow, Sheema Chawla, and Bipul Baibhav, MD.